Field assessment of BinaxNOW antigen tests as COVID-19 treatment entry point at a community testing site in San Francisco during evolving omicron surges.

Field assessment of BinaxNOW antigen tests as COVID-19 treatment entry point at a community testing site in San Francisco during evolving omicron surges.

COVID-19 oral treatments require initiation within 5 days of symptom onset. Although antigen tests are less sensitive than RT-PCR, rapid results could facilitate entry to treatment. We collected anterior nasal swabs for BinaxNOW and RT-PCR testing and clinical data at a walk-up, community site in Sa...

Full description

Bibliographic Details
Main Authors: John Schrom, Carina Marquez, Chung-Yu Wang, Aditi Saxena, Anthea M Mitchell, Salu Ribeiro, Genay Pilarowski, Robert Nakamura, Susana Rojas, Douglas Black, Maria G Contreras Oseguera, Edgar Castellanos Diaz, Joselin Payan, Susy Rojas, Diane Jones, Valerie Tulier-Laiwa, Aleks Zavaleta, Jacqueline Martinez, Gabriel Chamie, Carol Glaser, Kathy Jacobson, Maya Petersen, Joseph DeRisi, Diane V Havlir
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2023-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0283576

Internet

https://doi.org/10.1371/journal.pone.0283576

Similar Items